The relationship between serum dehydroepiandrosterone sulfate concentration and bone mineral density, lipids, and hormone replacement therapy in premenopausal and postmenopausal women

Journal of Women's Health

Volumn 13, Issue 9, 2004, Pages 993-999

  Osmanaǧaoǧlu, Mehmet A ^a   Okumuş, Bakiye ^a   Osmanaǧaoǧlu, Tayfun ^b   Bozkaya, Hasan ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b ACIBADEM HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL PLUS NORETHISTERONE ACETATE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PRASTERONE SULFATE; TIBOLONE; TRIACYLGLYCEROL;

ADULT; AGING; ANDROGEN BLOOD LEVEL; ARTICLE; ATHEROGENESIS; BODY MASS; BONE DENSITY; CORRELATION ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LINEAR REGRESSION ANALYSIS; LIPID BLOOD LEVEL; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; OSTEOPENIA; OSTEOPOROSIS; PARITY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR;

EID: 10944238524     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2004.13.993     Document Type: Article

References (33)

1. Lashansky G, Saenger P, Fishman K, et al. Normative data for adrenal steroidogenesis in a healthy pediatric population: Age- and sex-related changes after adrenocorticotropin stimulation. J Clin Endocrinol Metab 1991;73:674.
2. Rozenberg S, Ham H, Bosson D, Peretz A, Robyn C. Age, steroids and bone mineral content. Maturitas 1990;12:137.
3. Berdanier CD, Parente JA Jr, McIntosh MK. Is dehydroepiandrosterone an antiobesity agent? FASEB J 1993;7:414.
4. Kurzman ID, MacEwen EG, Haffa AL. Reduction in body weight and cholesterol in spontaneously obese dogs by dehydroepiandrosterone. Int J Obes 1990; 14:95.
5. Arad Y, Badimon JJ, Badimon L, Hembree WC, Ginsberg HN. Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbit. Arteriosclerosis 1989; 9:159.
6. Nordin BE, Robertson A, Seamark RF, et al. The relation between calcium absorption, serum dehydroepiandrosterone, and vertebral mineral density in postmenopausal women. J Clin Endocrinol Metab 1985;60:651.
7. Mazess RB. On aging bone loss. Clin Orthop 1982;165:239.
8. Stomati M, Hartmann B, Spinetti A, et al. Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-1 levels in postmenopausal women. J Endocrinol Invest 1996;19:535.
9. Castelo-Branco C, Martinez de Osaba MJ, Fortuny A, Iglesias X, Gonzalez-Merlo J. Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison. J Reprod Med 1995;40:556.
10. Casson PR, Elkind-Hirsch KE, Buster JE, Hornsby PJ, Carson SA, Snabes MC. Effect of postmenopausal estrogen replacement on circulating androgens. Obstet Gynecol 1997;90:995.
11. Liu CH, Laughlin GA, Fischer UG, Yen SS. Marked attenuation of ultradian and circadian rhythms of dehydroepiandrosterone in postmenopausal women: Evidence for a reduced 17,20-desmolase enzymatic activity. J Clin Endocrinol Metab 1990;71:900.
12. Kraemer RR, Synovitz LB, Gimpel T, Kraemer GR, Johnson LG, Castracane VD. Effect of estrogen on serum DHEA in younger and older women and the relationship of DHEA to adiposity and gender. Metabolism 2001;50:488.
13. Zborowski JV, Cauley JA, Talbott EO, Guzick DS, Winters SJ. Bone mineral density, androgens and the polycystic ovary: The complex and controversial issue of androgenic influence in female bone. J Clin Endocrinol Metab 2000;85:3496.
14. Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE. The localization of androgen receptors in human bone. J Clin Endocrinol Metab 1997;82:3493.
15. Munoz-Torres M, Jodar E, Quesada M, Escobar-Jimenez F. Bone mass in androgen-insensitivity syndrome: Response to hormonal replacement therapy. Calcif Tissue Int 1995;57:94.
16. Kleerekoper M, Nelson DA. Peripheral bone densitometry: An old friend revisited. Trans Am Clin Climatol Assoc 1998;109:62.
17. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227.
18. Barrett-Connor E, Goodman-Gruen D. Gender differences in insulin-like growth factor and bone mineral density association in old age: The Rancho Bernardo Study. J Bone Miner Res 1998;13:1343.
19. 3 in response to testosterone. Calcif Tissue Int 1997;60:485.
20. Tremollieres FA, Pouilles JM, Ribot C. Vertebral postmenopausal bone loss is reduced in overweight women: A longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab 1993;77:683.
21. Gordon CM, Goodman E, Emans SJ, et al. Physiologic regulators of bone turnover in young women with anorexia nervosa. J Pediatr 2002;141:64.
22. Turner RT, Lifrak ET, Beckner M, Wakley GK, Hannon KS, Parker LN. Dehydroepiandrosterone reduces cancellous bone osteopenia in ovariectomized rats. Am J Physiol 1990;258:673.
23. Fonseca E, Basurto L, Velazquez S, Zarate A. Hormone replacement therapy increases ACTH/dehydroepiandrosterone sulfate in menopause. Maturitas 2001;39:57.
24. Lobo RA, Goebelsmann U, Brenner PF, Mishell DR Jr. The effects of estrogen on adrenal androgens in oophorectomized women. Am J Obstet Gynecol 1982;142:471.
25. Dören M, Rubig A, Coelingh Bennink HJ, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 2001;75:554.
26. Seymour-Munn K, Adams J. Estrogenic effects of 5-androstene-3 beta, 17 beta-diol at physiological concentrations and its possible implication in the etiology of breast cancer. Endocrinology 1983;112:486.
27. Stomati M, Monteleone P, Casarosa E, et al. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol Endocrinol 2000;14:342.
28. Miklos S. Dehydroepiandrosterone sulphate in the diagnosis of osteoporosis. Acta Biomed Ateneo Parmense 1995;66:139.
29. Casson PR, Buster JE. DHEA administration to humans: Panacea or palaver? Semin Reprod Endocrinol 1995;13:247.
30. 4) to cardiovascular risk factors in postmenopausal women. Am J Epidemiol 1995;142:925.
31. Barrett-Connor E, Goodman-Gruen D. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Circulation 1995;91:1757.
32. Ravaglia G, Forti P, Maioli F, et al. The relationship of dehydroepiandrosterone sulfate (DHEAS) to endocrine-metabolic parameters and functional status in the oldest-old. Results from an Italian study on healthy free-living over-ninety-year-olds. J Clin Endocrinol Metab 1996;81:1173.
33. Nagata C, Takatsuka N, Kabuto M, Shimizu H. Association of dehydroepiandrosterone sulfate with serum HDL-cholesterol concentrations in post-menopausal Japanese women. Maturitas 1998;31:21.